A Bayesian optimal interval design for dose optimization with a randomization scheme based on pharmacokinetics...

Area of Science:

• Oncology
• Pharmacology
• Biostatistics

Background:

• Identifying the optimal dose (OD) is crucial for novel oncology therapies like targeted agents and immunotherapies.
• Pharmacokinetic (PK) data is vital for assessing drug exposure and predicting efficacy in cancer patients.
• Existing dose-finding methods may not fully leverage PK information for optimal dose selection.

Purpose of the Study:

• To propose a novel Bayesian optimal interval design for oncology dose-finding trials.
• To incorporate pharmacokinetic (PK) outcomes into a randomization scheme for dose optimization.
• To enhance the selection of the optimal dose (OD) for novel anticancer agents.

Main Methods:

• Development of a Bayesian optimal interval design incorporating PK data.
• Implementation of a randomization scheme based on PK outcomes.
• Simulation studies to compare the proposed design with existing methods.

Main Results:

• The proposed Bayesian design demonstrated superior performance in simulations.
• Higher percentage of correct optimal dose (OD) selection compared to other designs.
• More efficient allocation of patients to the optimal dose (OD) across various scenarios.

Conclusions:

• The proposed Bayesian optimal interval design effectively identifies the optimal dose (OD) in oncology trials.
• Integrating PK data improves dose selection accuracy and patient allocation efficiency.
• This PK-guided design offers a valuable advancement for novel cancer therapy development.